TY - JOUR T1 - Clinicopathologic Analysis With Immunohistochemistry for DNA Mismatch Repair Protein Expression in Synchronous Primary Endometrial and Ovarian Cancers JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 440 LP - 446 DO - 10.1097/IGC.0000000000000377 VL - 25 IS - 3 AU - Yusuke Kobayashi AU - Kanako Nakamura AU - Hiroyuki Nomura AU - Kouji Banno AU - Haruko Irie AU - Masataka Adachi AU - Miho Iida AU - Kiyoko Umene AU - Yuya Nogami AU - Kenta Masuda AU - Iori Kisu AU - Arisa Ueki AU - Wataru Yamagami AU - Fumio Kataoka AU - Akira Hirasawa AU - Eiichiro Tominaga AU - Nobuyuki Susumu AU - Daisuke Aoki Y1 - 2015/03/01 UR - http://ijgc.bmj.com/content/25/3/440.abstract N2 - Objective Synchronous primary endometrial and ovarian cancers have been an important topic in clinical medicine because it is sometimes difficult to distinguish whether there are 2 primary tumors or a single primary tumor and an associated metastasis. In addition, although these tumors are recommended for either immunohistochemistry for DNA mismatch repair (MMR) proteins or a microsatellite instability test in the Bethesda guidelines as Lynch syndrome–associated cancers, few studies have completed these analyses. In this study, we characterized the clinicopathologic features and the expression pattern of MMR proteins in synchronous primary endometrial and ovarian cancers.Methods Clinicopathologic features and the expression pattern of MMR proteins (MLH1, MSH2, and MSH6) were characterized and analyzed in 32 synchronous primary endometrial and ovarian cancers.Results Most synchronous cancers are endometrioid type (endometrioid/endometrioid) (n = 24, 75%), grade 1 (n = 19, 59.4%), and diagnosed as stage I (n = 15, 46.9%) in both endometrium and ovary. It is worth mentioning that 75% of the patients (n = 24) had endometriosis, which was more common (n = 21, 87.5%) in endometrioid/endometrioid cancers, whereas only 3 cases (37.5%) were of different histology (P = 0.018). Loss of expression of at least 1 MMR protein was observed in 17 (53.1%) of the endometrial tumors and in 10 (31.3%) of ovarian tumors. Only 4 cases (12.5%) that had specific MMR protein loss showed the same type of loss for both endometrial and ovarian tumors, in which 3 of the cases were losses in MLH1. One case showed concordant MSH6 protein loss, although the cases did not meet the Amsterdam criteria II.Conclusions These results suggest that most synchronous primary endometrial ovarian cancers are not hereditary cancers caused by germ line mutations but rather sporadic cancers. ER -